FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance --ATLANTA, Feb.

Femasys Inc. announced the achievement of CE mark certification for the FemBloc delivery system, marking it as the first regulatory approval in the world for a non-surgical permanent birth control ...

ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...

If you’re ready to make the life-altering decision to obtain permanent birth control, check out our list of 4 easiest forms of permanent birth control for men and women. While many people are actively ...

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...

Many women spend decades using birth control of one kind or another, except for when they’re trying to conceive or are pregnant. So when you know you’re done having babies or if you plan to stay child ...

FemBloc ® permanent birth control is a revolutionary first-of-its-kind non-surgical approach, that involves minimally-invasive delivery of a proprietary synthetic tissue adhesive to occlude the ...

ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of ...

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product ...

The number of women who sought permanent birth control via surgery increased in the wake of Roe v. Wade's overturn in 2022 Researchers saw a 51% increase in tubal ligation in four states “There was a ...